Results 101 to 110 of about 24,005 (199)

Combination of Vorinostat with Whole-brain Radiotherapy in the Treatment of Brain Metastases [PDF]

, 2010
Background: A third of patients with solid malignancies develop brain metastases. Expected overall survival is 4-7 months depending on age, performance status, and extracranial disease.
Choy, H., Dicker, A., Lawrence, Y. R., Pfeffer, R. M., Werner-Wasik, M.   +4 more
core   +2 more sources

Brief Review of Vorinostat

Clinical Medicine Insights: Therapeutics, 2010
The histone tails of histone octamers play an intricate role in transcription, and aid the histone interaction and binding with the negatively charged DNA phosphate backbone. Histone acetyl transferases and histone deacetylase inhibitors respectively accomplish acetylation and deacetylation of the lysine residue of the histone tail.
Colin McGuire, Jin Lee
openaire   +1 more source

Targeting class I histone deacetylases by the novel small molecule inhibitor 4SC-202 blocks oncogenic hedgehog-GLI signaling and overcomes smoothened inhibitor resistance [PDF]

, 2017
Aberrant activation of Hedgehog (HH)/GLI signaling is causally involved in numerous human malignancies, including basal cell carcinoma (BCC) and medulloblastoma. HH pathway antagonists targeting smoothened (SMO), an essential effector of canonical HH/GLI
Aberger, Fritz, Bartz, René, Canettieri, Gianluca, Coni, Sonia, Del Burgo, Pedro, Elmer, Dominik P, Gruber, Wolfgang, Kohlhof, Hella, Neureiter, Daniel, Peer, Elisabeth, Sternberg, Christina, Tesanovic, Suzana, Vitt, Daniel   +12 more
core   +1 more source

Supranuclear Palsy as an Initial Presentation of the Adult-Onset Niemann-Pick Type C

Neurology International
(1) Background: Niemann–Pick type C1 (NP-C1) is a lysosomal storage disorder that results in the defective trafficking of cholesterol and other cellular lipids in the endosomal–lysosomal pathway.
Ali A. Mohamed, Willy Gan, Denis Babici, Veronica Hagan, Raphael Wald, Marc Swerdloff   +5 more
doaj   +1 more source

Epigenetic priming of both tumor and NK cells augments antibody-dependent cellular cytotoxicity elicited by the anti-PD-L1 antibody avelumab against multiple carcinoma cell types

OncoImmunology, 2018
Checkpoint inhibitors targeting the PD-1/PD-L1 axis are promising immunotherapies shown to elicit objective responses against multiple tumor types, yet these agents fail to benefit most patients with carcinomas.
Kristin C. Hicks, Massimo Fantini, Renee N. Donahue, Angie Schwab, Karin M. Knudson, Sarah R. Tritsch, Caroline Jochems, Paul E. Clavijo, Clint T. Allen, James W. Hodge, Kwong Y. Tsang, Jeffrey Schlom, Sofia R. Gameiro   +12 more
doaj   +1 more source

Trends in the treatment of cutaneous T-cell lymphoma – critical evaluation and perspectives on vorinostat

Blood and Lymphatic Cancer: Targets and Therapy, 2012
Sophia Rangwala, Madeleine Duvic, Chunlei ZhangDepartment of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USAAbstract: Epigenetic modification with small molecule histone deacetylase inhibitors has been a promising new ...
Zhang CL, Duvic M, Rangwala S
doaj  

Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations.

PLoS ONE, 2016
Inhibitors of poly[ADP-ribose] polymerase 1 (PARPis) show promise for treatment of cancers which lack capacity for homologous recombination repair (HRR). However, new therapeutic strategies are required in order to overcome innate and acquired resistance
Michal Yalon, Liron Tuval-Kochen, David Castel, Itai Moshe, Inbal Mazal, Osher Cohen, Camila Avivi, Kineret Rosenblatt, Sarit Aviel-Ronen, Ginette Schiby, Joachim Yahalom, Ninette Amariglio, Raphael Pfeffer, Yaacov Lawrence, Amos Toren, Gideon Rechavi, Shoshana Paglin   +16 more
doaj   +1 more source

Novel CAR‐T Cells Specifically Targeting SIA‐CIgG Demonstrate Effective Antitumor Efficacy in Bladder Cancer

Advanced Science
Chimeric Antigen Receptor (CAR) T‐cell therapy is a promising cancer treatment method. However, its application in bladder cancer (BC) remains limited, partially because of the absence of appropriate target molecules.
Mengting Ding, Jiaxing Lin, Caipeng Qin, Yuhao Fu, Yiqing Du, Xiaoyan Qiu, Ping Wei, Tao Xu   +7 more
doaj   +1 more source

Anti-tumor effects of the histone deacetylase inhibitor vorinostat on canine urothelial carcinoma cells.

PLoS ONE, 2019
Canine urothelial carcinoma (cUC) is the most common tumor of the lower urinary tract in dogs. Although chemotherapy and radical surgery have improved the overall survival, most dogs with cUC succumb to metastasis or recurrence.
Shotaro Eto, Kohei Saeki, Ryohei Yoshitake, Sho Yoshimoto, Masahiro Shinada, Namiko Ikeda, Satoshi Kamoto, Yuiko Tanaka, Daiki Kato, Shingo Maeda, Masaya Tsuboi, James Chambers, Kazuyuki Uchida, Ryohei Nishimura, Takayuki Nakagawa   +14 more
doaj   +1 more source

Cell-based laboratory evaluation of coagulation activation by antineoplastic drugs for the treatment of lymphoid tumors

SAGE Open Medicine, 2016
Objectives: Combining vorinostat, L-asparaginase, and doxorubicin (Dox) led to improved response rates in the treatment of lymphoid tumors. However, deep-vein thrombosis has been noted as one of the most serious side effects with these drugs, and how ...
Misae Tsunaka, Reina Arai, Ayaka Ohashi, Takatoshi Koyama   +3 more
doaj   +1 more source